Oppenheimer initiated coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) in a note issued to investors on Tuesday,Benzinga reports. The brokerage set an “outperform” rating and a $60.00 price target on the stock. Oppenheimer’s price target would indicate a potential upside of 105.20% from the stock’s previous close.
A number of other research firms have also issued reports on FTH. Citigroup initiated coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target on the stock. BTIG Research reissued a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Finally, Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.75.
Check Out Our Latest Analysis on Sensei Biotherapeutics
Sensei Biotherapeutics Price Performance
Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, sell-side analysts forecast that Sensei Biotherapeutics will post -16.61 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the transaction, the insider owned 130,142 shares in the company, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 49,494 shares of company stock valued at $1,188,822 in the last ninety days. Insiders own 7.00% of the company’s stock.
Hedge Funds Weigh In On Sensei Biotherapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its stake in Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Finally, Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. 10.50% of the stock is owned by institutional investors and hedge funds.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Read More
- Five stocks we like better than Sensei Biotherapeutics
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
- Wintrust: A Quiet Regional Bank Posting Loud Results
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
